Adecatumumab
- Generic Name
- Adecatumumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 503605-66-1
- Unique Ingredient Identifier
- 000705ZASD
- Background
Adecatumumab is a recombinant human monoclonal antibody of the IgG1 subclass with a binding specificity to epithelial cell adhesion molecule (EpCAM). EpCAM (CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer.
- Indication
Investigated for use/treatment in breast cancer and prostate cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver Metastases
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-03-23
- Last Posted Date
- 2011-11-11
- Lead Sponsor
- Amgen Research (Munich) GmbH
- Target Recruit Count
- 35
- Registration Number
- NCT00866944
- Locations
- 🇩🇪
Klinikum der Johannes-Gutenberg Universität, Mainz, Germany
🇩🇪Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, Germany
🇩🇪Universitätsklinikum der LMU Grosshadern, München, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath